CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
R-GDP 方案作为复发/难治性弥漫大 B 细胞淋巴瘤挽救化疗的疗效
英文原题：Efficacy of R-GDP therapy as salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
查看英文原题
Efficacy of R-GDP therapy as salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
R-GDP已被确立为Rel/Ref DLBCL的有效挽救治疗方案。我们旨在阐明R-GDP治疗的疗效。我们纳入了41例连续接受R-GDP治疗作为挽救化疗的Rel/Ref DLBCL患者，这些患者于2014年1月至2024年8月期间在我院接受治疗。33例患者接受R-GDP作为二线方案，而8例接受R-GDP作为三线或更后线方案。ORR为70.7%。25例复发患者中有23例（92%）对R-GDP治疗有反应，而16例难治患者中仅有6例有反应（37.5%）。关于缓解持续时间，19例晚期复发（至少12个月）和6例早期复发（少于12个月）患者的缓解率分别为94.7%和83.3%（p = 0.43）。
总体而言，2年PFS和OS率分别为48.8%和74.2%。18例缓解者接受了ASCT，ASCT后2年PFS为61.2%。尽管CAR-T 被推荐用于Rel/Ref DLBCL患者，但鉴于即时CAR-T 治疗的可用性有限，R-GDP是一个现实的选择。有必要开展包括基因组谱在内的进一步研究，以确定能够预测Rel/Ref DLBCL对R-GDP反应的因素。
展开英文摘要原文
R-GDP has been established as an effective salvage treatment for Rel/Ref DLBCL.
We aimed to clarify the efficacy of R-GDP therapy. We included 41 consecutive patients with Rel/Ref DLBCL, who received R-GDP therapy as salvage chemotherapy at our hospital between January 2014 and August 2024. Thirty-three patients received R-GDP therapy as a 2nd-line regimen, whereas 8 received R-GDP as a 3rd or later-line regimen.
The ORR was 70. 7%. 23 out of 25 relapsed patients (92%) responded to R-GDP therapy, whereas only 6 out of 16 refractory patients responded (37. 5%). With regard to the duration of response, the response rates in 19 patients with late relapse (at least 12 months) and 6 with early relapse (less than 12 months) were 94. 7% and 83. 3% (p = 0. 43).
Overall, the 2-year PFS and OS rates were 48. 8% and 74. 2%, respectively. 18 responders underwent ASCT with a 2-year PFS after ASCT of 61. 2%. Although CAR-T is recommended in patients with Rel/Ref DLBCL, R-GDP is a realistic option given the limited availability of immediate CAR-T therapy.
Further studies including genomic profiles are warranted to identify factors that can predict a response to R-GDP in Rel/Ref DLBCL.
论文信息
- 作者
- Hatano K、Honda S、Yamaguchi T、Tominaga R、Yokoyama D、Noguchi A、Furuki S、Koyama S
- 第一作者单位
- Division of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan.Japan
- 通讯作者单位
- Division of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan; Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan. Electronic address: ycanda-tky@umin.ac.jp.Japan
- 期刊
- Leukemia research2026 Oct
- 原文标识
- PubMed 42685545 · DOI 10.1016/j.leukres.2026.108301